SAN JOSE, Calif., June 17 /PRNewswire-FirstCall/ -- Oclaro, Inc. (Nasdaq: OCLR) has announced the shipment of its 200,000th Fluorescence Filter for biomedical and analytical instrumentation markets. Oclaro filters are used by leading companies in a wide range of biomedical and analytical applications, including clinical diagnostics, drug discovery, gene quantification, blood analysis, and disease detection. The latest offerings from the Oclaro filter portfolio are on display at LASER World of Photonics 2009 in Munich.
Oclaro Clarity(TM) Filters utilise proprietary AED (Advanced Energetic Deposition) coating technology to produce high performance band pass filters, dichroic mirrors, and laser beam combiners. The AED technology facilitates an environmentally stable hard coating that offers superb resistance, high transmission, and high out-of-band blocking. The state of the art Oclaro automated production facilities enable repeatability and high yield at large volumes, ensuring cost effective manufacturing and value for our customers.
"Oclaro Fluorescence Filters are based on proven telecom technology boasting zero failures in over 65 billion recorded hours of operation," said Yves LeMaitre, EVP and General Manager of the Oclaro Advanced Photonic Solutions (APS) division. "We have been manufacturing Clarity Fluorescence Filters for the biomedical market for over five years and have the expertise to deliver quality, innovative products to this demanding and dynamic market."
The APS division leverages the Oclaro telecom expertise and channels it into biomedical and industrial applications. The Clarity fluorescence filter is a prime example of bringing the best of telecom technology manufacturing into biomedical applications, which represents a strategic focus for the APS division of Oclaro.
Oclaro was formerly Bookham, Inc. prior to its merger with Avanex Corporation last April. The company also recently announced entering into a definitive agreement with Newport Corporation which, if the transaction closes, will, among other things, provide Oclaro with a portion of the Newport Spectra Physics high power laser diode business, and provide Newport with the existing New Focus business. Oclaro will continue to leverage its cutting edge, high reliability laser diode manufacturing facilities to service industrial, defense and medical markets with high power lasers, VCSELs and Thin Film Filters.
Notes to editors
Oclaro, with headquarters in San Jose, California, is a tier 1 provider of high performance optical components, modules and subsystems to the telecommunications market, and is one of the largest providers to metro and long haul network applications. Oclaro, the result of the combination of Bookham, Inc. and Avanex Corporation, leverages proprietary core technologies and vertically integrated product development to provide its broad customer base with cost-effective and innovative optical solutions. The company's Advanced Photonics Division is chartered with driving Oclaro's diversification and growth into new markets, leveraging Oclaro's strong brand, chip design and manufacturing expertise. Oclaro is a global company, with leading chip fabrication facilities in the U.K., Switzerland and Italy, and manufacturing sites in the US, Thailand and China.
Oclaro, the Oclaro logo and all other Oclaro product names and slogans are trademarks or registered trademarks of Oclaro, Inc. in the USA or other countries.
|SOURCE Oclaro, Inc.|
Copyright©2009 PR Newswire.
All rights reserved